Mirum Pharmaceuticals, Inc.
LIVMARLI (maralixibat)
additional rare cholestatic conditions
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for LIVMARLI (maralixibat) in additional rare cholestatic conditions are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“topline results expected in Q4 2026”